Mogrify Limited (Mogrify), a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, has held the second closing of its Series A financing of USD17 million, bringing the total raised to USD33 million in this round

Read more

Source: Private Equity Wire